Roles
- Associate Professor of Clinical Medicine
- Chief Medical Director, UHealth Doral
-
Biography
David H Kerman, MD, is an Associate Professor in the Division of Gastroenterology at the University of Miami Miller School of Medicine. He earned his medical degree at the University of Texas Health Science Center-Houston. His postdoctoral training includes an internship and residency in Internal Medicine at Rush University in Chicago, IL, followed by a year as Chief Resident in the Department of Medicine at Rush. He completed his fellowship in Gastroenterology at the University of Miami/Jackson Memorial Hospital. He spent 6 years as the Director of the Gastroenterology and Hepatology Fellowship Program at UM/Jackson and 2 years as the Chief Medical Officer for the UM Department of Medicine. Dr Kerman is currently serving as Chief Medical Director for the UHealth Doral facility. His clinical expertise focuses on complex Inflammatory Bowel Disease and recurrent C difficile infection. At the UM Crohn’s and Colitis Center, Dr Kerman sees patients from South Florida, Central and South America, and the Caribbean. He serves as Primary Investigator and Co-investigator on the latest clinical trials for patients with IBD. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 29 clinical trials.
-
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Closed
-
This is an investigational drug study, to evaluate the efficacy of filgotinib in subjects in stable clinical remission on 200 mg filgotinib q.d. for whom the dose was decreased to 100 mg q.d. compared to subjects remaining on 200 mg q.d.
- Principal Investigator: David Kerman
- Study Phase: Phase III
- Enrollment Status: Closed
-
The purpose of this study is to evaluate the efficacy, safety, tolerability and PK following oral administration of CCR6 antagonist, PF-07054894, in the treatment of adult participants with moderate to severe UC.
- Principal Investigator: David Kerman
- Study Phase: Phase I
- Enrollment Status: Closed
-
A phase 2b, dose ranging study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohns Disease
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Closed
-
This Phase 2, double-blind, placebo-controlled, randomized study will evaluate the safety, efficacy, and microbiota changes of VE202 in the treatment of biologic-nave patients; 18 to 75 years of age with mild-to-moderate ulcerative colitis (UC)
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Closed
-
This trial is composed of 2 parts: A) Part A is a randomized, double-blind, placebo-controlled trial and B) Part B is an optional open-label treatment (OLT) arm for patients who experience an on-trial central laboratory-positive C. difficile-related diarrhea through Week 8
- Principal Investigator: David Kerman
- Study Phase: Phase III
- Enrollment Status: Closed
-
A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have Participated in ADMIRE II Study
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy
- Principal Investigator: David Kerman
- Study Phase: Phase II/III
- Enrollment Status: Closed
-
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
- Principal Investigator: David Kerman
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
- Principal Investigator: David Kerman
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
- Principal Investigator: David Kerman
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
- Principal Investigator: David Kerman
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
- Principal Investigator: David Kerman
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis
- Principal Investigator: David Kerman
- Study Phase: Phase 3
- Enrollment Status: Closed
-
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. The study consists of 3 sub-studies: Sub-Study 1 is a single-arm, open-label sub-study designed to identify duvakitug treatment responders; Sub-Study 2 is the placebo-controlled pivotal induction sub-study; Sub-Study 3 is an extended induction sub-study for non-responders.
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Open
-
EFC18325 is a multinational, multicenter, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active UC. The study consists of 3 sub-studies: Sub-Study 1 is a single-arm, open-label study identifying duvakitug treatment responders, who can be enrolled into the Pivotal Maintenance Study (EFC18359). Sub-Study 2 is the placebo-controlled Pivotal Induction study including 2 duvakitug doses and placebo. Treatment responders from both sub-studies (Sub-Study 1 and Sub-Study 2) can be randomized into the Maintenance Study (EFC18359), and non-responders can be randomized into Sub-Study 3 for extended induction. The primary objective consists of assessing the efficacy of duvakitug as induction therapy in the treatment of moderately to severely active UC compared to placebo. Secondary Objective is to assess the efficacy of duvakitug using multiple measures of disease activity.
- Principal Investigator: David Kerman
- Study Phase: Phase III
- Enrollment Status: Open
-
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study followed by an open label long term extension period to evaluate the efficacy andsafety of SAR442970 in adults with moderate to severe CD. SAR442970 represents a novel therapy which could simultaneously target 2 key pathways in CD to improve disease control.
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Open
-
The primary objective for this study is to evaluate the safety and efficacy of lutikizumab when compared to adalimumab in adult subjects with moderately to severely active UC, by IL-1signature status.
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Closed
-
This study will evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in patients with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Closed
-
The objective of this study is to assess the efficacy, safety, and tolerability of RZB SC induction treatment in comparison with placebo in subjects with moderately to severely active CD.
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis
- Principal Investigator: David Kerman
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
The purpose of this study is to evaluate the safety and tolerability of AGMB-129 in patients with fibrostenotic CD, compared to placebo.This is a randomized, double-blind, placebo-controlled, parallel, multicenter, phase 2a study in participants with fibrostenotic CD.This study consists of 3 periods (a screening period, a double-blind, placebo-controlled treatment period, and safety follow-up).
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Closed
-
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapy. This study is the maintenance phase of previous induction studies ABX464-106.
- Principal Investigator: David Kerman
- Study Phase: TBD
- Enrollment Status: Closed
